|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen J, Zhang F, Wang J, Hu L, Chen J, Xu
G and Wang Y: LncRNA LINC01512 promotes the progression and
enhances oncogenic ability of lung adenocarcinoma. J Cell Biochem.
118:3102–3110. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gridelli C, Rossi A and Maione P:
Treatment of non-small-cell lung cancer: State of the art and
development of new biologic agents. Oncogene. 22:6629–6638. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen CH, Lai JM, Chou TY, Chen CY, Su LJ,
Lee YC, Cheng TS, Hong YR, Chou CK, Whang-Peng J, et al: VEGFA
upregulates FLJ10540 and modulates migration and invasion of lung
cancer via PI3K/AKT pathway. PLoS One. 4:e50522009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ogawa E, Takenaka K, Katakura H, Adachi M,
Otake Y, Toda Y, Kotani H, Manabe T, Wada H and Tanaka F:
Perimembrane Aurora-A expression is a significant prognostic factor
in correlation with proliferative activity in non-small-cell lung
cancer (NSCLC). Ann Surg Oncol. 15:547–554. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rachet B, Woods LM, Mitry E, Riga M,
Cooper N, Quinn MJ, Steward J, Brenner H, Estève J, Sullivan R and
Coleman MP: Cancer survival in England and Wales at the end of the
20th century. Br J Cancer. 99 Suppl 1:S2–S10. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stewart DJ: Tumor and host factors that
may limit efficacy of chemotherapy in non-small cell and small cell
lung cancer. Crit Rev Oncol Hematol. 75:173–234. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mercer TR, Dinger ME and Mattick JS: Long
non-coding RNAs: Insights into functions. Nat Rev Genet.
10:155–159. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ren K, Xu R, Huang J, Zhao J and Shi W:
Knockdown of long non-coding RNA KCNQ1OT1 depressed chemoresistance
to paclitaxel in lung adenocarcinoma. Cancer Chemother Pharmacol.
80:243–250. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Carrizosa DR and Gold KA: New strategies
in immunotherapy for non-small cell lung cancer. Transl Lung Cancer
Res. 4:553–559. 2015.PubMed/NCBI
|
|
12
|
Lian Y, Cai Z, Gong H, Xue S, Wu D and
Wang K: HOTTIP: A critical oncogenic long non-coding RNA in human
cancers. Mol Biosyst. 12:3247–3253. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ma C, Shi X, Zhu Q, Li Q, Liu Y, Yao Y and
Song Y: The growth arrest-specific transcript 5 (GAS5): A pivotal
tumor suppressor long noncoding RNA in human cancers. Tumour Biol.
37:1437–1444. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu L, Jin L, Zhang W and Zhang L: Roles of
long non-coding RNA CCAT2 in cervical cancer cell growth and
apoptosis. Med Sci Monit. 22:875–879. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pawar K, Hanisch C, Vera Palma SE,
Einspanier R and Sharbati S: Down regulated lncRNA MEG3 eliminates
mycobacteria in macrophages via autophagy. Sci Rep. 6:194162016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shang C, Guo Y, Hong Y and Xue YX: Long
non-coding RNA TUSC7, a target of miR-23b, plays tumor-suppressing
roles in human gliomas. Front Cell Neurosci. 10:2352016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu Q, Han L, Yan W, Ji X, Han R, Yang J,
Yuan J and Ni C: miR-489 inhibits silica-induced pulmonary fibrosis
by targeting MyD88 and Smad3 and is negatively regulated by lncRNA
CHRF. Sci Rep. 6:309212016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jin J, Sun Z, Yang F, Tang L, Chen W and
Guan X: miR-19b-3p inhibits breast cancer cell proliferation and
reverses saracatinib-resistance by regulating PI3K/Akt pathway.
Arch Biochem Biophys. 645:54–60. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shang C, Guo Y, Zhang J and Huang B:
Silence of long noncoding RNA UCA1 inhibits malignant proliferation
and chemotherapy resistance to adriamycin in gastric cancer. Cancer
Chemother Pharmacol. 77:1061–1067. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu G, Xiang T, Wu QF and Wang WX: Long
noncoding RNA H19-derived miR-675 enhances proliferation and
invasion via RUNX1 in gastric cancer cells. Oncol Res. 23:99–107.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yan J, Dang Y, Liu S, Zhang Y and Zhang G:
LncRNA HOTAIR promotes cisplatin resistance in gastric cancer by
targeting miR-126 to activate the PI3K/AKT/MRP1 genes. Tumour Biol.
Nov 30–2016.(Epub ahead of print). View Article : Google Scholar
|
|
23
|
Tao Y, Han T, Zhang T, Ma C and Sun C:
LncRNA CHRF-induced miR-489 loss promotes metastasis of colorectal
cancer via TWIST1/EMT signaling pathway. Oncotarget. 8:36410–36422.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang K, Liu F, Zhou LY, Long B, Yuan SM,
Wang Y, Liu CY, Sun T, Zhang XJ and Li PF: The long noncoding RNA
CHRF regulates cardiac hypertrophy by targeting miR-489. Circ Res.
114:1377–1388. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tytgat GA, Voûte PA, Takeuchi S, Miyoshi I
and Rutgers M: Meta-iodobenzylguanidine uptake in platelets,
megakaryoblastic leukaemia cell lines MKPL-1 and CHRF-28-11 and
erythroleukaemic cell line HEL. Eur J Cancer. 31A:603–606. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Schick BP, Petrushina I, Brodbeck KC and
Castronuevo P: Promoter regulatory elements and DNase
I-hypersensitive sites involved in serglycin proteoglycan gene
expression in human erythroleukemia, CHRF 288-11, and HL-60 cells.
J Biol Chem. 276:24726–24735. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Scholl S, Kirsch C, Böhmer FD and Klinger
R: Signal transduction of c-Kit receptor tyrosine kinase in CHRF
myeloid leukemia cells. J Cancer Res Clin Oncol. 130:711–718. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen L, Yan KP, Liu XC, Wang W, Li C, Li M
and Qiu CG: Valsartan regulates TGF-β/Smads and TGF- β/p38 pathways
through lncRNA CHRF to improve doxorubicin-induced heart failure.
Arch Pharm Res. 41:101–109. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hennessy BT, Smith DL, Ram PT, Lu Y and
Mills GB: Exploiting the PI3K/AKT pathway for cancer drug
discovery. Nat Rev Drug Discov. 4:988–1004. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xu S, Sui S, Zhang J, Bai N, Shi Q, Zhang
G, Gao S, You Z, Zhan C, Liu F and Pang D: Downregulation of long
noncoding RNA MALAT1 induces epithelial-to-mesenchymal transition
via the PI3K-AKT pathway in breast cancer. Int J Clin Exp Pathol.
8:4881–4891. 2015.PubMed/NCBI
|
|
31
|
Yang C, Li X, Wang Y, Zhao L and Chen W:
Long non-coding RNA UCA1 regulated cell cycle distribution via CREB
through PI3-K dependent pathway in bladder carcinoma cells. Gene.
496:8–16. 2012. View Article : Google Scholar : PubMed/NCBI
|
